Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
- Conditions
- Interventions
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 94
- Registration Number
- NCT01889407
- Locations
- 🇨🇳
Bing Xu, GuangZhou, Guangdong, China
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01876953
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Pure Erythroid Leukemia (M6b)Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableUntreated Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Monocytic Leukemia (M5b)
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT01831232
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myelomonocytic Leukemia (M4)Adult Pure Erythroid Leukemia (M6b)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Erythroleukemia (M6a)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)
- Interventions
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2023-02-03
- Target Recruit Count
- 55
- Registration Number
- NCT01822015
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 754
- Registration Number
- NCT01802333
- Locations
- 🇺🇸
Flaget Memorial Hospital, Bardstown, Kentucky, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT01794702
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Alisertib for Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01779843
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT01773408
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Cancer Therapy & Research Ctr; Dept Institute for Drug Development, San Antonio, Texas, United States
🇨🇦McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-01-28
- Target Recruit Count
- 48
- Registration Number
- NCT01700413
- Locations
- 🇪🇸
Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Spain
🇪🇸Hospital Clinic I Provincial de Barcelona, Barcelona, Spain
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT01692197
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.